|
Accession number;06A0654482
|
| Title;Review/Advances in Neurological Therapeutics (2005). Neurological Infections. |
| Author;
AYABE MITSUYOSHI
(Kurume Univ., JPN)
NODA KAZUTO
(Kurume Univ., JPN)
|
Journal Title;Neurological Therapeutics
|
Journal Code:X0110A
|
ISSN:0916-8443
|
|
VOL.23;NO.4;PAGE.365-368(2006)
|
| Figure&Table&Reference;REF.9 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Recent advances in the treatment of neurological infections are here described based on papers published in 2005. Tuberculous meningitis: Whether HIV infection alters the presentation and outcome of tuberculous meningitis is unknown. Thwaites GE et al. reported that HIV infection did not alter the neurological features of tuberculous meningitis but significantly reduced the survival rate. Fungal meningitis: There is limited published information regarding the clinical use of voriconazole for cryptococcosis. Voriconazole achives good levels in cerebrospinal fluid and may be a particularly valuable drug for refractory cryptococcal meningoencephalitis. Viral encephalitis: The Japanese Society for Neuroinfectious Diseases had issued guidelines to aid the diagnosis and treatment of herpes simplex encephalitis (HSE). The JSND recommends that all patients with HSE receive intravenous aciclovir 10 mg/kg every 8 h for 14 days. Kamei S et al. described that combination therapy using both acyclovir and corticosteroid represented one of the predictors of outcome in HSE. Oxman MN et al. reported that the zoster vaccine markedly reduced morbidity form herpes zoster and postherpetic neuralgia among older adults. The previous study had failed to show the efficancy of cytarabine in HIV-infected patients with PML. Langer-Gould A et al. reported a patient with multiple sclerosis in whom PML developed during treatment with interferon betala and natalizumab that had improved his condition after treatment with intravenous cytarabine. It is possible that the extensive breakdown of the blood-brain barrier improved penetration of cytarabine into the central nervous system. Todd NV et al. administrated pentosan polysulphate (PPS) to the cerebral ventricles of patients with variant Creutzfeldt-Jakob disease and follow-up CT scans demonstrated progressive brain atrophy during PPS administration. (author abst.) |
|
|
|
Related Articles;
|
